Your browser doesn't support javascript.
loading
An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.
Szederjesi, A; Baronciani, L; Budde, U; Castaman, G; Lawrie, A S; Liu, Y; Montgomery, R; Peyvandi, F; Schneppenheim, R; Várkonyi, A; Patzke, J; Bodó, I.
  • Szederjesi A; Szent István and Szent László Hospital, Budapest, Hungary.
  • Baronciani L; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Budde U; Laboratory of Hemostasis, University Hospital Hamburg, Hamburg, Germany.
  • Castaman G; Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy.
  • Lawrie AS; Haemostasis Research Unit, University College London, London, UK.
  • Liu Y; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Montgomery R; MFRC, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Peyvandi F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Schneppenheim R; University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
  • Várkonyi A; Szent István and Szent László Hospital, Budapest, Hungary.
  • Patzke J; Department of Assay Development, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany.
  • Bodó I; Szent István and Szent László Hospital, Budapest, Hungary.
J Thromb Haemost ; 16(8): 1604-1613, 2018 Aug.
Article en En | MEDLINE | ID: mdl-29897666
ABSTRACT
Essentials New VWF activity assays are increasingly used but information on their comparability is limited. This is an ISTH SSC-organized study (expert labs, 5 countries) to compare all available assays. VWF activity by six assays correlated well with each other. The new assays show improved characteristics - minor differences are noted.

SUMMARY:

Background Several new assays have become available to measure von Willebrand factor (VWF) activity. The new assays appear to have improved performance characteristics compared with the old reference standard, ristocetin cofactor activity (VWFRCo), but information is limited about how they compare with VWFRCo and each other. Methods The von Willebrand factor Subcommittee of the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) designed a collaborative study involving expert laboratories from several countries to compare available tests with each other and with VWFRCo. Eight laboratories from five countries were provided with blinded samples from normal healthy individuals and well-characterized clinical cases. Laboratories measured VWF activity using all tests available to them; data from six laboratories, not affected by thawing during transportation, are included in this study. Results All tests correlated well with VWFRCo activity (r-values ranged from 0.963 to 0.989). Slightly steeper regression lines for VWFAb and VWFGPIbM were clinically insignificant. The new assays showed improved performance characteristics. Of the commercially available assays, the VWFGPIbR using the AcuStar system was the most sensitive and could reliably detect VWF activity below 1 IU dL-1 . The lower limit of the measuring interval for the VWFGPIbM and the VWFGPIbR assays was in the 3-4 and 3-6 IU dL-1 range, respectively. Inter-laboratory variation was also improved for most new assays. Conclusion All VWF activity assays correlated well with each other and the VWFRCo assay. The slight differences in characteristics found in the COMPASS-VWF study will assist the VWF community in interpreting and comparing activity results.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2018 Tipo del documento: Article